Our focus is on developing a product with significant potential for treating radiation-induced fibrosis. Disitertide has shown considerable promise in preclinical studies, effectively inhibiting TGF-β signaling, a key driver of fibrosis.
For instance, Cruz-Morande et al (PMID: 35448191) demonstrated remarkable muscle antifibrotic effects of the peptide in animal models exposed to radiation. It reduced collagen deposition, minimized fibrosis markers, and improved tissue architecture, highlighting its potential as a therapeutic tool.
These findings underscore the peptide’s promise in transforming treatments for radiation-induced fibrosis, representing a step forward in addressing the long-term effects of radiation therapy
